share_log

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) PT Lowered to €23.00

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) PT Lowered to €23.00

Fresenius Medical Care AG&Co.KGaA(紐約證券交易所代碼:FMS)PT降至23.00歐元
kopsource ·  2022/08/05 06:01

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) had its price objective cut by JPMorgan Chase & Co. from €51.00 ($52.58) to €23.00 ($23.71) in a report published on Monday morning, The Fly reports.

Fresenius Medical Care AG&Co.KGaA(紐約證券交易所代碼:FMS-GET評級)在週一上午發佈的一份報告中,摩根大通將其目標價從51.00歐元(52.58美元)下調至23.00歐元(23.71美元)。

Several other equities research analysts also recently weighed in on FMS. Jefferies Financial Group raised shares of Fresenius Medical Care AG & Co. KGaA from an underperform rating to a buy rating and upped their target price for the stock from $30.30 to $33.70 in a research note on Monday, June 27th. DZ Bank downgraded shares of Fresenius Medical Care AG & Co. KGaA from a buy rating to a hold rating in a research note on Friday, July 29th. UBS Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a buy rating to a neutral rating in a research note on Friday, July 29th. StockNews.com downgraded shares of Fresenius Medical Care AG & Co. KGaA from a strong-buy rating to a buy rating in a research note on Friday, July 15th. Finally, Truist Financial cut their target price on shares of Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a hold rating on the stock in a research note on Wednesday, June 22nd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Fresenius Medical Care AG & Co. KGaA has an average rating of Hold and a consensus price target of $49.01.

其他幾位股票研究分析師最近也對FMS發表了看法。6月27日週一,傑富瑞金融集團在一份研究報告中將費森尤斯醫療保健股份公司的股票評級從表現不佳上調為買入,並將該股的目標價從30.30美元上調至33.70美元。DZ銀行在7月29日星期五的一份研究報告中將Fresenius Medical Care AG&Co.KGaA的股票評級從買入下調至持有。7月29日,瑞銀集團在一份研究報告中將費森尤斯醫療保健股份公司KGaA的股票評級從買入下調至中性。在7月15日星期五的一份研究報告中,StockNews.com將Fresenius Medical Care AG&Co.KGaA的股票評級從強力買入下調至買入。最後,Truist Financial在6月22日(星期三)的一份研究報告中將費森尤斯醫療保健股份公司(Fresenius Medical Care AG&Co.KGaA)的目標價從34.00美元下調至27.00美元,並對該股設定了持有評級。一位研究分析師對該股的評級為賣出,7位分析師給出了持有評級,4位分析師給出了該公司的買入評級。根據MarketBeat.com的數據,Fresenius Medical Care AG&Co.KGaA的平均評級為持有,共識目標價為49.01美元。

Get
到達
Fresenius Medical Care AG & Co. KGaA
費森尤斯醫療保健股份公司
alerts:
警報:

Fresenius Medical Care AG & Co. KGaA Price Performance

費森尤斯醫療保健股份公司KGaA價格表現

Fresenius Medical Care AG & Co. KGaA stock opened at $18.44 on Monday. The company's 50 day simple moving average is $24.60 and its 200-day simple moving average is $29.72. The company has a market capitalization of $10.81 billion, a price-to-earnings ratio of 11.75, a price-to-earnings-growth ratio of 0.85 and a beta of 1.02. Fresenius Medical Care AG & Co. KGaA has a 1 year low of $18.16 and a 1 year high of $40.85. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.93 and a current ratio of 1.18.

Fresenius Medical Care AG&Co.KGaA股票週一開盤報18.44美元。該公司的50日簡單移動均線切入位為24.60美元,200日簡單移動均線切入位為29.72美元。該公司市值為108.1億美元,市盈率為11.75倍,市盈率為0.85倍,貝塔係數為1.02。Fresenius Medical Care AG&Co.KGaA的一年低點為18.16美元,一年高位為40.85美元。該公司的負債權益比率為0.47,速動比率為0.93,流動比率為1.18。

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) last released its quarterly earnings results on Wednesday, May 4th. The company reported $0.38 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.30 by $0.08. The business had revenue of $5.10 billion for the quarter, compared to the consensus estimate of $4.97 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.42% and a return on equity of 6.70%. As a group, equities research analysts expect that Fresenius Medical Care AG & Co. KGaA will post 1.79 earnings per share for the current year.
Fresenius Medical Care AG&Co.KGaA(紐約證券交易所市場代碼:FMS-GET Rating)最近一次發佈季度收益報告是在5月4日星期三。該公司公佈本季度每股收益(EPS)為0.38美元,高於分析師普遍預期的0.30美元和0.08美元。該業務本季度營收為51億美元,而市場普遍預期為49.7億美元。費森尤斯醫療保健股份公司KGaA的淨利潤率為4.42%,股本回報率為6.70%。作為一個整體,股票研究分析師預計Fresenius Medical Care AG&Co.KGaA本年度每股收益將達到1.79美元。

Institutional Inflows and Outflows

機構資金流入和流出

Several large investors have recently modified their holdings of FMS. Russell Investments Group Ltd. acquired a new position in shares of Fresenius Medical Care AG & Co. KGaA in the 4th quarter valued at $1,152,000. Janney Montgomery Scott LLC boosted its stake in Fresenius Medical Care AG & Co. KGaA by 7.1% during the 4th quarter. Janney Montgomery Scott LLC now owns 31,996 shares of the company's stock worth $1,039,000 after purchasing an additional 2,114 shares during the period. Commonwealth Equity Services LLC grew its position in Fresenius Medical Care AG & Co. KGaA by 6.4% during the 4th quarter. Commonwealth Equity Services LLC now owns 13,583 shares of the company's stock worth $440,000 after purchasing an additional 817 shares during the last quarter. Yousif Capital Management LLC purchased a new position in Fresenius Medical Care AG & Co. KGaA during the 4th quarter worth $295,000. Finally, Riverwater Partners LLC acquired a new position in Fresenius Medical Care AG & Co. KGaA in the fourth quarter valued at $325,000. Institutional investors and hedge funds own 4.73% of the company's stock.

幾家大型投資者最近調整了對FMS的持股。羅素投資集團有限公司在第四季度收購了價值1,152,000美元的Fresenius Medical Care AG&Co.KGaA股票。詹尼·蒙哥馬利·斯科特有限責任公司(Janney Montgomery Scott LLC)在第四季度將其在Fresenius Medical Care AG&Co.KGaA的持股增加了7.1%。Janney Montgomery Scott LLC現在持有31,996股該公司股票,價值1,039,000美元,在此期間又購買了2,114股。聯邦股權服務公司第四季度在Fresenius Medical Care AG&Co.KGaA的持倉增加了6.4%。Federal Equity Services LLC在上個季度額外購買了817股後,現在擁有13,583股該公司股票,價值44萬美元。Yousif Capital Management LLC在第四季度購買了費森尤斯醫療保健股份公司(Fresenius Medical Care AG&Co.KGaA)價值29.5萬美元的新頭寸。最後,Riverwater Partners LLC在第四季度收購了Fresenius Medical Care AG&Co.KGaA的一個新頭寸,價值32.5萬美元。機構投資者和對衝基金持有該公司4.73%的股票。

About Fresenius Medical Care AG & Co. KGaA

關於費森尤斯醫療保健股份公司

(Get Rating)

(獲取評級)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Fresenius Medical Care AG&Co KGaA在德國、北美和國際上提供透析護理和相關的透析護理服務。它通過門診透析診所網絡提供透析治療以及相關的實驗室和診斷服務;材料、培訓和患者支持服務,包括臨牀監測、後續援助和安排將用品運送到患者住所;以及根據合同向美國醫院提供為住院的終末期腎病(ESRD)患者和急性腎功能衰竭患者提供的透析服務。

Featured Articles

專題文章

  • Get a free copy of the StockNews.com research report on Fresenius Medical Care AG & Co. KGaA (FMS)
  • 3 Hotel Stocks to Consider Checking into After Earnings
  • How Does Freeport McMoran Inc Compare to Its Sector Competitors?
  • Can FuelCell Energy Surge Higher This Year?
  • Is It Time to Take a Ride on Cedar Fair Stock?
  • Time To Take A Serious Look At Nikola Stock As Production Starts
  • 免費獲取StockNews.com關於Fresenius Medical Care AG&Co.KGaA(FMS)的研究報告。
  • 盈利後考慮登記的3家酒店股票
  • 自由港麥克莫蘭公司與其行業競爭對手相比如何?
  • 燃料電池能源今年會飆升嗎?
  • 是時候在雪松公平股票上兜風了嗎?
  • 隨着生產開始,是時候認真看看尼古拉·斯托克了

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

接受Fresenius Medical Care AG&Co.KGaA Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Fresenius Medical Care AG&Co.KGaA和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論